+Vote!
Seeking Alpha (Free subscription) | 5 hours ago
Eli Lilly (LLY) is expected to report Q2 earnings before market open Thursday, July 24, with a conference call scheduled for 9:00 am ET. Guidance Analysts are looking for a profit of 99c on revenue of $5.03B. The consensus range is 97c to $1.02 for EPS, and revenue of $4.91B to $5.20B, according to First Call. For Q1, Lilly reported Q1 EPS ex-items 92c vs. consensus of 96c. Complete Story »
+Vote!
soulful sepulcher (Free subscription) | yesterday
Judge Weinstein : FDA: Eli Lilly: Accountability! Philip Dawdy:Furious Seasons Mental health news blog:October 05, 2007 "The Zyprexa Chronicles: Interview With Mother Of Zyprexa Victim The following is an interview with Ellen Liversidge, mother of Rob. He was a 39-year-old with bipolar disorder who died in 2002 after taking Zyprexa. Today is the fifth anniversary of his death." From the
+Vote!
Furious Seasons (Free subscription) | 07/22/2008
Late last week, US District Court Judge Jack Weinstein shot off his mouth in an opinion he filed in the midst of a merry-goround of opinions being filed as various Zyprexa cases under his purview are shaped up to march toward trial or settlement. Recently, Weinstein pressed Eli Lilly to settle all outstanding Zyprexa claims and various estimates put that figure at over $7 billion. Lilly has already...
+Vote!
bioethics.com (Free subscription) | 07/21/2008
The biggest drug makers are known for cut-throat competition, not collaboration. But last week Pfizer, Merck and Eli Lilly bucked that trend, announcing the creation of a joint company called Enlight BioSciences to help fund and develop enabling technologies to speed drug development. The company, formed with the help of PureTech Ventures, a venture capital [...]
1Vote!
Red Orbit (Free subscription) | 07/20/2008
By Arnold, Matthew PFIZER FOLLOWED Eli Lilly's lead in posting a list of $10 million in grants and charitable contributions the company made to medical, scientific and patient organizations during the first quarter of 2008 as "part of an ongoing drive throughout the company to increase transparency." The disclosures include medical education grants, fellowship and scholarship support for institutions,...
+Vote!
Seeking Alpha (Free subscription) | 07/17/2008
Mike Huckman submits: More than ten years after Pfizer (PFE) brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctors. The study, paid for by Clialis-maker Eli Lilly (LLY), shows nearly 40 percent of men have never broached the subject with their physician, even though 82 percent...
+Vote!
Patent Docs (Free subscription) | 07/17/2008
By Sherri Oslick -- Earlier this month by consent judgment, the Paragraph IV litigation between Eli Lilly and Glenmark Pharmaceuticals over Lilly's ADHD drug Strattera® was terminated. Per the parties' stipulation, Glenmark agreed that the patent-in-suit was neither invalid nor unenforceable, and further agreed to a permanent injunction enjoining it from manufacturing or selling its generic version...
+Vote!
soulful sepulcher (Free subscription) | 07/17/2008
Teva gets generic Zyprexa. Teva-Novopharm, known for gaining generic patents of drugs, (as I wrote about earlier regarding AstraZeneca remaining in control of the Seroquel patent until 2012) has a generic version of the antipsychotic that carries a black box warning for diabetes Zyprexa. Eli Lilly has been in hot water for a long time with Zyprexa, and now that there is a generic version of
+Vote!
Notes from Dr. RW (Free subscription) | 07/15/2008
Recent blistering attacks on the Surviving Sepsis Guidelines have made a large appeal to public distrust of the pharmaceutical industry (specifically Eli Lilly) with little regard for the actual evidence. I originally made that point here and here . Critics implied that the guidelines were little more than marketing for Lilly’s activated protein C ( Xigris ). They were proven wrong when the guideline...
+Vote!
Seeking Alpha (Free subscription) | 07/14/2008
Dividends4Life submits: Linked here is a PDF copy of my analysis of Eli Lilly and Co. ( alt.1 , alt.2 ). Below are some highlights from the above linked analysis: Company Description: Eli Lilly and Company (LLY) discovers, develops, manufactures and sells prescription drugs that offers a wide range of treatments for neurological disorders, diabetes, cancer, and other conditions. The company also sells...
2Vote!
Seeking Alpha (Free subscription) | 07/11/2008
Mike Huckman submits: Big pharma makes strange bedfellows. Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY) announced yesterday morning that they've launched a joint venture of sorts called, "Enlight Biosciences" . They're doing it with the help of the Boston-based VC ("Venture Creation," the website says, not "Venture Capital") firm PureTech Ventures . All together the partners are kicking in as much...
+Vote!
Fiercebiotech (Free subscription) | 07/10/2008
Shares of the UK's Entelos surged after the company reported a licensing pact with Eli Lilly. The pact covers access to Entelos' database of 630 drug profiles, which is used to test an experimental therapy's safety and toxicity. Report
+Vote!
Fiercebiotech (Free subscription) | 07/10/2008
Three of the biggest pharma companies on the planet are joining forces to back an unusual venture aimed at developing "breakthrough" discovery technology that can reduce the frequency of trial failures and save them huge amounts of money. Eli Lilly, Merck and Pfizer--which often compete on new therapies--are joining forces with PureTech Ventures to provide $39 million to finance the launch of Enlight...
+Vote!
PR News Wire (Free subscription) | 07/10/2008
Pharmaceutical and Academic Luminaries Combine Forces to Address Innovation
Bottleneck
BOSTON, July 10 /PRNewswire/ -- Enlight Biosciences, a new Boston-based
company conceived by PureTech Ventures together with several major
pharmaceutical companies, announced today that it will direct up to $39M to
advance breakthrough technologies that can fundamentally alter drug
discovery and development. Enlight...
+Vote!
sunilnair | 12/25/2007
Eli Lilly & Co.: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated...
